Bridgebio Pharma LLC, an active creator of lean new ventures built around a common core, has closed a new $299.2 million financing round to support its efforts to target genetic disease through existing R&D programs. Its work spans subsidiaries focused on dermatology, oncology, cardiology, neurology, endocrinology, renal disease and ophthalmology. The round was co-led by existing investors KKR and Viking Global Investors. Other existing investors included Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital and Hercules Capital. New investors Sequoia Capital and an unidentified blue-chip long-term investor also participated.